Akari Therapeutics (AKTX) 20-F 31 Mar 17 2016 FY Annual report (foreign) Financial data

Document And Entity Information

Document And Entity Information	12 Months Ended
	Dec. 31, 2016shares
Document Information [Line Items]
Document Type	20-F
Amendment Flag	false
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Entity Registrant Name	Akari Therapeutics Plc
Entity Central Index Key	1,541,157
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Trading Symbol	AKTX
Entity Common Stock, Shares Outstanding	1,177,693,383

COMBINED AND CONSOLIDATED BALAN

COMBINED AND CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Current Assets:
Cash and cash equivalents	$ 34,098,812	$ 68,919,995
Short-term investments	10,021,963	0
Prepaid expenses and other current assets	1,513,006	728,126
Receivable from related party	0	10,366
Total Current Assets	45,633,781	69,658,487
Restricted cash	142,168	142,079
Property and equipment, net	58,364	40,513
Patent acquisition costs, net	39,365	52,483
Total Assets	45,873,678	69,893,562
Current Liabilities:
Accounts payable	2,214,313	4,320,588
Accrued expenses	1,837,647	408,222
Liability related to options and warrants	7,662,808	16,396,158
Total Current Liabilities	11,714,768	21,124,968
Other long-term liability	56,360	49,069
Total liabilities	11,771,128	21,174,037
Commitments and Contingencies
Shareholders' Equity:
Share capital of GBP .01 par value Authorized: 5,000,000,000 ordinary shares; issued and outstanding: 1,177,693,383 at December 31, 2016 and 2015, respectively	18,340,894	18,340,894
Additional paid-in capital	90,979,363	87,018,764
Accumulated other comprehensive (loss) income	(280,097)	156,480
Accumulated deficit	(74,937,610)	(56,796,613)
Total Shareholders' Equity	34,102,550	48,719,525
Total Liabilities and Shareholders' Equity	$ 45,873,678	$ 69,893,562

COMBINED AND CONSOLIDATED BALA3

COMBINED AND CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2016	Dec. 31, 2015
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	5,000,000,000	5,000,000,000
Common stock, shares issued	1,177,693,383	1,177,693,383
Common stock, shares outstanding	1,177,693,383	1,177,693,383

COMBINED AND CONSOLIDATED STATE

COMBINED AND CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Operating Expenses:
Research and development costs	$ 17,306,001	$ 5,799,076	$ 1,616,204
General and administrative expenses	9,940,557	5,502,214	303,095
Excess consideration	0	19,283,280	0
Total Operating Expenses	27,246,558	30,584,570	1,919,299
Loss from Operations	(27,246,558)	(30,584,570)	(1,919,299)
Other Income (Expense):
Interest income	143,195	20,705	91
Changes in fair value of option and warrant liabilities - gains	8,733,350	11,408,231	0
Financing expense	0	(22,973,138)	0
Foreign currency exchange gain (loss)	272,985	(90,588)	(22,909)
Interest expense	0	(3,053,948)	(5,436)
Other expenses	(43,969)	(44,224)	0
Total Other Income (Expense)	9,105,561	(14,732,962)	(28,254)
Net Loss	(18,140,997)	(45,317,532)	(1,947,553)
Other Comprehensive (Loss) Income:
Foreign Currency Translation Adjustment	(436,577)	110,399	79,438
Comprehensive Loss	$ (18,577,574)	$ (45,207,133)	$ (1,868,115)
Loss per common share (basic and diluted)	$ (0.02)	$ (0.05)	$ (0.02)
Weighted average common shares (basic and diluted)	1,177,693,383	852,088,530	85,515,588

COMBINED AND CONSOLIDATED STAT5

COMBINED AND CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($)	Total	Varleigh Immuno Pharmaceuticals Ltd [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income [Member]	Accumulated Deficit [Member]
Beginning Balance at Dec. 31, 2013	$ 400,690	$ 1,888,435	$ 1,119,122	$ 6,958,018	$ (33,357)	$ (9,531,528)
Beginning Balance (in shares) at Dec. 31, 2013		11,727,149	72,108,370
Issuance of share capital (related to the recapitalization of Volution)	3,690,723	$ 0	$ 10,091,682	(6,400,959)	0	0
Issuance of share capital (related to the recapitalization of Volution) (in shares)		0	650,237,230
Payment of share subscription receivable	0	$ 0	$ 0	0	0	0
Dissolution of Varleigh	0	$ (1,888,435)	$ 0	1,888,435	0	0
Dissolution of Varleigh (shares)		(11,727,149)	0
Comprehensive Loss	(1,868,115)	$ 0	$ 0	0	79,438	(1,947,553)
Ending Balance at Dec. 31, 2014	2,223,298	$ 0	$ 11,210,804	2,445,494	46,081	(11,479,081)
Ending Balance (in shares) at Dec. 31, 2014		0	722,345,600
Issuance of share capital related to acquisition (Celsus shares outstanding at date of acquisition)	20,339,140	$ 0	$ 926,567	19,412,573	0	0
Issuance of share capital related to acquisition (Celsus shares outstanding at date of acquisition) (in shares)		0	55,636,283
Issuance of share capital related to financing, net of issuance costs	69,574,354	$ 0	$ 6,144,075	63,430,279	0	0
Issuance of share capital related to financing, net of issuance costs (in shares)		0	395,881,100
Issuance of share capital for advisory fees	750,000	$ 0	$ 59,448	690,552	0	0
Issuance of share capital for advisory fees (in shares)		0	3,830,400
Stock based compensation	1,039,866	$ 0	$ 0	1,039,866	0	0
Comprehensive Loss	(45,207,133)	0	0		110,399	(45,317,532)
Ending Balance at Dec. 31, 2015	48,719,525	$ 0	$ 18,340,894	87,018,764	156,480	(56,796,613)
Ending Balance (in shares) at Dec. 31, 2015		0	1,177,693,383
Stock based compensation	3,933,222	$ 0	$ 0	3,933,222	0	0
Dissolution of subsidiary	27,377	0	0	27,377	0	0
Comprehensive Loss	(18,577,574)	0	0		(436,577)	(18,140,997)
Ending Balance at Dec. 31, 2016	$ 34,102,550	$ 0	$ 18,340,894	$ 90,979,363	$ (280,097)	$ (74,937,610)
Ending Balance (in shares) at Dec. 31, 2016		0	1,177,693,383

COMBINED AND CONSOLIDATED STAT6

COMBINED AND CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Cash Flows from Operating Activities:
Net loss	$ (18,140,997)	$ (45,317,532)	$ (1,947,553)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	39,944	10,162	4,942
Stock-based compensation	3,933,222	1,039,866	0
Compensation expense	0	750,000	0
Amortization of debt discount	0	3,031,304	0
Excess consideration	0	19,283,280	0
Financing expense	0	22,973,138	0
Changes in fair value of the liability for options and warrants	(8,733,350)	(11,408,231)	0
Foreign currency exchange gains	(272,985)	0	0
(Increase) decrease in assets:
Prepaid expenses and other current assets	(785,876)	913,788	(8,422)
(Decrease) increase in liabilities:
Accounts payable and accrued expenses	(671,784)	3,755,173	474,209
Other liabilities	7,291	3,469	0
Total adjustments	(6,483,538)	40,351,949	470,729
Net Cash Used in Operating Activities	(24,624,535)	(4,965,583)	(1,476,824)
Cash Flows from Investing Activities:
Purchase of property and equipment	(54,750)	(10,560)	0
Cash received from reverse acquisition	0	1,410,577	0
Purchase of short-term investments	(46,120,172)	0	0
Maturities of short-term investments	36,098,209	0	0
Receivable from related party	10,081	(8,219)	0
Net Cash (Used) Provided by Investing Activities	(10,066,632)	1,391,798	0
Cash Flows from Financing Activities:
Proceeds from shareholder loans	0	3,031,304	432,353
Payments of shareholder loans	0	(3,561,239)	0
Proceeds from issuance of shares	0	75,000,000	3,690,723
Share issuance costs	0	(5,425,646)	0
Proceeds from stock subscription	0	0	112,300
Net Cash Provided by Financing Activities	0	69,044,419	4,235,376
Effect of Exchange Rates on Cash and Cash Equivalents	(130,016)	121,893	15,262
Net (Decrease) Increase in Cash and Cash Equivalents	(34,821,183)	65,592,527	2,773,814
Cash and Cash Equivalents, beginning	68,919,995	3,327,468	553,654
Cash and Cash Equivalents, end	34,098,812	68,919,995	3,327,468
Cash paid during the year for:
Interest	$ 0	$ 22,945	$ 5,400

Nature of Business

Nature of Business	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations [Text Block]	NOTE 1 - Nature of Business Akari Therapeutics, Plc, (the “Company” or “Akari”), formerly Celsus Therapeutics Plc (“Celsus”), is incorporated in the United Kingdom. The Company is a clinical-stage biopharmaceutical company focused on developing inhibitors of acute and chronic inflammation, specifically the complement system, the eicosanoid system and the bioamine system for the treatment of rare and orphan diseases. On September 18, 2015, Celsus Therapeutics Plc completed its acquisition of all of the capital stock of Volution Immuno Pharmaceuticals SA (“Volution”), from RPC Pharma Limited (“RPC”), Volution’s sole shareholder, in exchange for ordinary shares, par value £ 0.01 each representing 100 In connection with the consummation of the Acquisition, Celsus issued an aggregate of 722,345,600 92.85 91.68 721:1 The Company, as defined in the accompanying notes to the Combined and Consolidated Financial Statements, refers to Volution prior to the Acquisition and Akari subsequent to the completion of the Acquisition. In addition, on September 18, 2015, the Company completed a private placement of an aggregate of 3,958,811 395,881,100 75 18.945 33.3 5.4 69.6 Volution was originally incorporated in Switzerland as a private limited company and commenced business on October 9, 2013. On October 23, 2013, Varleigh Immuno Pharmaceuticals Ltd (“Varleigh”), a UK limited company, transferred certain patent rights to Volution in exchange for a payment of approximately $ 107,000 65,000 On July 3, 2015, the shareholders of Volution exchanged their shares for RPC shares with no changes in individual share ownerships. This qualified as a reorganization. The Company is subject to a number of risks similar to those of clinical stage companies, including dependence on key individuals, uncertainty of product development and generation of revenues, dependence on outside sources of capital, risks associated with clinical trials of products, dependence on third-party collaborators for research operations, need for regulatory approval of products, risks associated with protection of intellectual property, and competition with larger, better-capitalized companies. Successful completion of the Company’s development program and, ultimately, the attainment of profitable operations is dependent upon future events, including obtaining adequate financing to fulfill its development activities and achieving a level of revenues adequate to support the Company’s cost structure. There are no assurances that the Company will be able to obtain additional financing on favorable terms, or at all or successfully market its products.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	NOTE 2 - Summary of Significant Accounting Policies The Combined and Consolidated Financial Statements include the accounts of the Company, Volution and Volution Immuno Pharmaceuticals Ltd (a private limited company incorporated in England and Wales), its wholly-owned subsidiary, which was incorporated in London on August 22, 2014. On September 6, 2016, Volution Immuno Pharmaceuticals Ltd was dissolved. All intercompany transactions have been eliminated. The functional currency of the Company is U.S. dollars as that is the primary economic environment in which the Company operates as well as the currency in which it has been financed. The reporting currency of the Company is U.S. Dollars. The Company translated its non-U.S. operations’ assets and liabilities denominated in foreign currencies into U.S. dollars at current rates of exchange as of the balance sheet date and income and expense items at the average exchange rate for the reporting period. Translation adjustments resulting from exchange rate fluctuations are recorded as foreign currency translation adjustments, a component of accumulated other comprehensive (loss) income. Gains or losses from foreign currency transactions are included in foreign currency exchange gains (losses). The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that may affect the reported amounts of assets, liabilities, equity, revenue, expenses and related disclosure of contingent assets and liabilities. Management’s estimates and judgments include assumptions used in the evaluation of impairment and useful lives of intangible assets (patents), accrued liabilities, deferred income taxes, liabilities related to stock options and warrants, stock-based compensation and various other assumptions that are believed to be reasonable under the circumstances. Actual results may differ from those estimates under different assumptions or conditions. – The carrying amounts of financial instruments, including cash and cash equivalents, short-term investments, restricted cash, receivable from related party and accounts payable approximate fair value due to their short-term maturities. The Company’s liabilities related to options and warrants relate to equity and debt financing rounds and options related to RPC, and are recognized on the balance sheet at their fair value, with changes in the fair value accounted for in the Statements of Comprehensive Loss and included in changes in fair value of option/warrant liabilities. – The Company considers all highly-liquid investments with original maturities of 90 days or less at the time of acquisition to be cash equivalents. The Company had no cash equivalents as of December 31, 2016 and December 31, 2015. Short-term investments consist of certificates of deposit that are expected to be converted into cash within one year. Restricted cash is collateral for a letter of credit related to the Company’s office lease. Prepaid expenses and other current assets consist principally of VAT receivables and prepaid expenses. Property and equipment are stated at cost, net of accumulated depreciation. Years Computers, peripheral, and scientific equipment 3 Office furniture and equipment 3 Depreciation expense for the years ended December 31, 2016, 2015 and 2014 was $ 36,898 7,040 3,051 – The Company reviews all long-lived assets for impairment whenever events or circumstances indicate the carrying amount of such assets may not be recoverable. Recoverability of assets to be held or used is measured by comparison of the carrying value of the asset to the future undiscounted net cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment recognized is measured by the amount by which the carrying value of the asset exceeds the discounted future cash flows expected to be generated by the asset. – Patent acquisition costs and related capitalized legal fees are amortized on a straight-line basis over the shorter of the legal or economic life. The estimated useful life is 22 – As part of the process of preparing the Combined and Consolidated Financial Statements, it requires the estimate of accrued expenses. This process involves identifying services that third parties have performed on the Company’s behalf and estimating the level of service performed and the associated cost incurred on these services as of each balance sheet date in the Company’s Combined and Consolidated Financial Statements. Examples of estimated accrued expenses include contract service fees in conjunction with pre-clinical and clinical trials and professional service fees. In connection with these service fees, the Company estimates are most affected by its understanding of the status and timing of services provided relative to the actual services incurred by the service providers. In the event that the Company does not identify certain costs that have been incurred or it under or over-estimates the level of services or costs of such services, our reported expenses for a reporting period could be understated or overstated. The date on which certain services commence, the level of services performed on or before a given date, and the cost of services are often subject to our judgment. The Company makes these judgments based upon the facts and circumstances known to us in accordance with U.S. GAAP. Costs associated with research and development are expensed as incurred. Research and development expenses include, among other costs, personnel expenses, costs incurred by outside laboratories, manufacturers’ and other accredited facilities in connection with clinical trials and preclinical studies. Research and development expense for the years ended December 31, 2016, 2015 and 2014 was $ 17,306,001 5,799,076 1,616,204 577,671 Stock-based compensation expense is recorded using the fair-value based method for all awards granted. Compensation costs for stock options and awards is recorded in earnings (loss) over the requisite service period based on the fair value of those options and awards. For employees, fair value is estimated at the grant date and for non-employees fair value is re-measured at each reporting date as required by ASC 718, “Compensation-Stock Compensation,” and ASC 505-50, “Equity-Based Payments to Non-Employees.” Fair values of awards granted under the share option plans are estimated using a Black-Scholes option pricing model. The determination of fair value for stock-based awards on the date of grant using an option pricing model requires management to make certain assumptions regarding a number of complex and subjective variables. The Company classifies its stock-based payments as either liability-classified awards or as equity-classified awards. The Company remeasures liability-classified awards to fair value at each balance sheet date until the award is settled. The liability for liability-classified awards generally is equal to the fair value of the award as of the balance sheet date multiplied by the percentage vested at the time. The Company charges (or credits) the change in the liability amount from one balance sheet date to another to changes in fair value of option/warrant liabilities. Financial instruments that subject the Company to credit risk consist of cash and cash equivalents. The Company maintains cash and cash equivalents with well-capitalized financial institutions. At times, those amounts may exceed insured limits. The Company has no significant concentrations of credit risk. – The Company accounts for income taxes in accordance with the accounting rules that require an asset and liability approach to accounting for income taxes based upon the future expected values of the related assets and liabilities. Deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and for tax loss and credit carry forwards, and are measured using the expected tax rates estimated to be in effect when such basis differences reverse. Valuation allowances are established, if necessary, to reduce the deferred tax asset to the amount that will, more likely than not, be realized. The Company follows the provisions of ASC 740 “ Accounting for Uncertainty in Income Taxes Accounting for Uncertainty in Income Taxes – Basic earnings (loss) per common share is computed by dividing net income (loss) available to common shareholders by the weighted-average number of Ordinary Shares outstanding during the period. Diluted earnings (loss) per common share is computed by dividing net income (loss) available to common shareholders by the sum of (1) the weighted-average number of Ordinary Shares outstanding during the period, (2) the dilutive effect of the assumed exercise of options and warrants using the treasury stock method and (3) the dilutive effect of other potentially dilutive securities. Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. The Company’s other comprehensive income (loss) is comprised of foreign currency translation adjustments. Balance January 1, 2014 $ (33,357) Net current period other comprehensive income 79,438 Balance December 31, 2014 46,081 Net current period other comprehensive income 110,399 Balance December 31, 2015 156,480 Net current period other comprehensive loss (436,577) Balance December 31, 2016 $ (280,097) In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers” (“ASU 2014-09”), which supersedes nearly all existing revenue recognition guidance under GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing GAAP. On July 9, 2015, the FASB voted to defer the effective date by one year to December 15, 2017 for interim and annual reporting periods beginning after that date. Early adoption of ASU 2014-09 is permitted but not before the original effective date (annual periods beginning after December 15, 2016). When effective, ASU 2014-09 prescribes either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients; or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). The Company does not believe the adoption of this standard will have a material impact on our financial position, results of operations or related financial statement disclosures. In February 2016, the FASB issued ASU No. 2016-02, Leases In March 2016, the FASB issued ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting In August 2016, the FASB issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments In October 2016, the FASB issued ASU 2016-16, Intra-Entity Transfers of Assets Other Than Inventory In November 2016, the FASB issued ASU, 2016-18, Restricted Cash cash flows from investing activities and to certain beginning and ending cash and cash equivalent totals shown on Combined and Consolidated Statement of Cash Flows. The Company does not believe the adoption of this standard will have a material impact on its financial position, results of operations or related financial statement disclosures.

Reverse Acquisition

Reverse Acquisition	12 Months Ended
	Dec. 31, 2016
Business Combinations [Abstract]
Business Combination Disclosure [Text Block]	NOTE 3 – Reverse Acquisition The Company completed the Acquisition as discussed in Note 1. Based on the terms of the Acquisition and since the Volution securityholders owned approximately 91.68 The acquisition consideration for accounting purposes consisted of Ordinary Shares and the fair value of vested options and warrants issued by Celsus that were outstanding at the date of the Acquisition immediately prior to closing. Assets and liabilities of Celsus were measured at fair value and added to the assets and liabilities of Volution. The consolidated financial statements reflect the historical financial statements of Volution as our historical financial statements, except for the legal capital which reflects our legal capital (Ordinary Shares). In connection with the consummation of the Acquisition, the Company issued an aggregate of 722,345,600 Purchase Consideration Fair value of Celsus Ordinary Shares outstanding $ 20,034,625 (a) Fair value of Celsus share options 277,461 (2,516,690 options) Fair value of Celsus warrants 27,054 (1,782,246 warrants) Total purchase price $ 20,339,140 (a) computed by multiplying 55,636,283 0.3601 Allocation of Purchase Consideration Under the acquisition method of accounting, the total purchase price was allocated to tangible and identifiable intangible assets acquired and liabilities assumed of Celsus on the basis of their estimated fair values as of the transaction closing date on September 18, 2015. The excess of the total purchase price over the fair value of assets acquired and liabilities assumed was allocated to excess consideration. Cash and cash equivalents $ 1,410,577 Restricted cash 142,079 Prepaid expenses and other assets acquired 1,672,028 Excess consideration 19,283,280 Liabilities related to options and warrants (1,800,154) Other assumed liabilities (368,670) $ 20,339,140 The Company believes that the historical values of Celsus’s current assets and current liabilities approximate fair value based on the short-term nature of such items. Excess consideration is calculated as the difference between the fair value of the consideration realized and the values assigned to the identifiable tangible and intangible assets acquired and liabilities assumed. The Company recorded this non-cash charge in the Combined and Consolidated Statements of Comprehensive Loss for the year ended December 31, 2015 due to the fact that goodwill could not be justified and was considered fully impaired.

Patent Acquisition Costs

Patent Acquisition Costs	12 Months Ended
	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets Disclosure [Text Block]	NOTE 4 – Patent Acquisition Costs 22 December 31, December 31, 2016 2015 Patent acquisition and related costs $ 92,434 $ 95,050 Less: Accumulated amortization (53,069) (42,567) $ 39,365 $ 52,483 Amortization of patent acquisition costs for the years ended December 31, 2016, 2015 and 2014 was $ 3,046 3,122 1,891 Year Ended Amount 2017 $ 2,944 2018 2,944 2019 2,944 2020 2,944 2021 2,944 Thereafter 24,645 $ 39,365

Loans Payable - Shareholders

Loans Payable - Shareholders	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	NOTE 5 – Loans Payable – Shareholders At a Volution shareholder meeting held on June 22, 2015, Volution raised short-term working capital in the form of loans from shareholders of approximately $ 3 15 15 26 26 3 23 Interest expense included in the Combined and Consolidated Statements of comprehensive loss related to loans for the years ended December 31, 2016, 2015 and 2014 was $ 0 3,053,948 5,436

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2016
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	NOTE 6 – Fair Value Measurements Fair value of financial instruments: The estimated fair value of financial instruments has been determined by the Company using available market information and valuation methodologies. Considerable judgment is required in estimating fair values. Accordingly, the estimates may not be indicative of the amounts the Company could realize in a current market exchange. The carrying amounts of cash and cash equivalents, short-term investments, receivable from related party, restricted cash and accounts payable approximate their fair value due to the short-term maturity of such instruments. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. As a basis for considering such assumptions, ASC 820, “Fair Value Measurements and Disclosures” establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value: Level 1 - quoted prices in active markets for identical assets or liabilities; Level 2 - inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; or Level 3 - unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. December 31, 2016 December 31, 2015 Carrying Fair Carrying Fair Fair Amount Value Amount Value Value $ $ $ $ Levels Liability related to RPC options 7,627,970 7,627,970 15,711,017 15,711,017 3 Liability related to warrants 34,838 34,838 685,141 685,141 3 In accordance with ASC No. 820, the Company measures its liabilities related to options and warrants on a recurring basis at fair value. The liabilities related to options and warrants are classified within Level 3 value hierarchy because the liabilities are based on present value calculations and external valuation models whose inputs include market interest rates, estimated operational capitalization rates, volatilities and illiquidity. Unobservable inputs used in these models are significant. December 31, 2016 December 31, 2015 Carrying Fair Carrying Fair Fair Amount Value Amount Value Value $ $ $ $ Levels Reference Cash and cash equivalents 34,098,812 34,098,812 68,919,995 68,919,995 1 Note 2 Short-term investment 10,021,963 10,021,963 - - 1 Note 2 Restricted cash 142,168 142,168 142,079 142,079 1 Note 2 Accounts payable 2,214,313 2,214,313 4,320,588 4,320,588 1 - Liability related to options and warrants 7,662,808 7,662,808 16,396,158 16,396,158 3 Note 6 On September 18, 2015, the Acquisition date, warrants to purchase 5,617,977 share or warrant issuance at less than $0.1958 price share or exercise price per share 188,303 5,806,280 0.18945 34,838 650,303 The Company accounts for the liability warrants issued in accordance with ASC 815, “Derivatives and Hedging” as a freestanding liability instrument that is measured at fair value at each reporting date, based on its fair value, with changes in the fair values being recognized in the Company’s Combined and Consolidated Statements of Comprehensive Loss as a change in fair value of option/warrant liabilities. The fair value of warrants granted was measured using the Binomial method of valuation. December 31, 2016 2015 Expected dividend yield 0 % 0 % Expected volatility 73.39 % 233.0 % Risk-free interest 0.51 % 0.75 % Expected life 0.26 years 1.26 years In June 2015, the Company raised short-term working capital in the form of loans from shareholders of approximately $ 3 15 15 26 26 3 3 23 As of December 31, 2016, the fair value of the RPC options was $ 7,627,970 8,083,047 15,711,017 Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock Determining Whether an Instrument (or Embedded Feature) Is Indexed to an Entity’s Own Stock December 31, December 31, 2016 2015 Fair value measurements using input type Level 3 Warrants $ 34,838 $ 685,141 RPC options 7,627,970 15,711,017 Liabilities related to stock options and warrants $ 7,662,808 $ 16,396,158 Fair value of liabilities related to stock options and warrants Balance at December 31, 2014 $ - Balance at September 18, 2015 (Acquisition) 1,800,154 Changes in values of liabilities related to options and warrants (11,408,231) Value of liability related to options - transfer in 26,004,235 Balance at December 31, 2015 16,396,158 Changes in values of liabilities related to options and warrants (8,733,350) Balance at December 31, 2016 $ 7,662,808

Shareholders' Equity

Shareholders' Equity	12 Months Ended
	Dec. 31, 2016
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	NOTE 7 – Shareholders’ Equity Share Capital – The Company has 5,000,000,000 1,177,693,383 On September 18, 2015, in connection with the Acquisition, 55,636,283 On September 18, 2015, the Company completed a private placement of 395,881,100 75 0.18945 On September 18, 2015, the Company issued 3,830,400 750,000 500,000 Share option plan – Upon completion of the Acquisition, the Company assumed the former Celsus 2014 Equity Incentive Plan (the “Plan”). In accordance with the Plan, the number of shares that may be issued upon exercise of options under the Plan, shall not exceed 141,142,420 61,770,222 Weighted average Weighted Weighted remaining average average contractual Aggregate Number exercise grant date term intrinsic of shares price fair value (in years) value Options outstanding as of January 1, 2016 61,362,198 $ 0.34 9.7 $ - Changes during the period: Granted 22,700,000 $ 0.14 $ 0.09 Forfeited (4,690,000) $ 0.21 $ 0.12 Options outstanding at December 31, 2016 79,372,198 $ 0.29 8.7 $ - Exercisable options at December 31, 2016 25,486,486 $ 0.34 8.7 $ - Weighted average Number grant date of shares fair value Non-vested options at December 31, 2015 58,480,181 $ 0.21 Options granted 22,700,000 $ 0.09 Options vested (22,604,469) $ 0.18 Non-vested options forfeited (4,690,000) $ 0.12 Non-vested at December 31, 2016 53,885,712 $ 0.24 On March 23, 2016, the Company granted 11,000,000 0.141 1,300,000 0.18 7,800,000 0.145 6,500,000 1,300,000 1,300,000 0.080621 1,300,000 0.080621 The Company accounts for awards of equity instruments issued to employees and directors under the fair value method of accounting and recognize such amounts, upon vesting, in general administrative and research and development expenses within its Combined and Consolidated Statements of Comprehensive Loss. The Company measures compensation cost for all share-based awards at fair value on the date of grant and recognize compensation expense in its Combined and Consolidated Statements of Comprehensive Loss using the straight-line method over the service period over which it expects the awards to vest. The Company estimates the fair value of all time-vested options as of the date of grant using the Black-Scholes option valuation model, which was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable. Option valuation models require the input of highly subjective assumptions, including the expected share price volatility, which is calculated based on the historical volatility of the Company’s Ordinary Shares. The Company uses a risk-free interest rate, based on the U.S. Treasury instruments in effect at the time of the grant, for the period comparable to the expected term of the option. Given its limited history with share option grants and exercises, the Company uses the “simplified” method in estimating the expected term, the period of time that options granted are expected to be outstanding, for its grants. The Company classifies its stock-based payments as either liability-classified awards or as equity-classified awards. The Company remeasures liability-classified awards to fair value at each balance sheet date until the award is settled. The Company measures equity-classified awards at their grant date fair value and do not subsequently remeasure them. The Company has classified its stock-based payments which are settled in common stock as equity-classified awards and share-based payments that are settled in cash as liability-classified awards. Compensation costs related to equity-classified awards generally are equal to the grant-date fair value of the award amortized over the vesting period of the award. The liability for liability-classified awards generally is equal to the fair value of the award as of the balance sheet date multiplied by the percentage vested at the time. The Company charges (or credits) the change in the liability amounts from one balance sheet date to another to compensation expense. December 31, 2016 2015 2014 Expected dividend yield 0 % 0 % - Expected volatility 74.18%-80.71% 71.28%-81.79% - Risk-free interest 1.03%-1.52% 1.51%-2.27% - Expected life 5.5-6.25 years 5.5-10 years - Remaining Options Weighted Options contractual outstanding average Weighted exercisable life (years Weighted Exercise at remaining average at for average price December contractual exercise December exercisable exercise (range) ($) 31, 2016 life (years) price ($) 31, 2016 options) price ($) 0.08-0.19 24,313,351 9.31 0.15 6,950,054 9.22 0.15 0.32 53,597,347 8.72 0.32 17,239,932 8.72 0.32 0.60-0.75 290,000 7.20 0.72 290,000 7.20 0.72 0.98-1.56 311,500 3.24 1.31 311,500 3.24 1.31 2.00 860,000 6.73 2.00 695,000 6.73 2.00 79,372,198 25,486,486 During the year ended December 31, 2016, the Company recorded approximately $ 3,933,000 8,957,000 2.7 Warrants to service providers and investors – Number of Exercise Grant date warrants Price Expiration date 2012 warrants 1,383,086 $ 1.72 - $2.25 January 16, 2017-November 30, 2017 2013 warrants 399,160 $ 2.00 January 16, 2018-September 17, 2018 1,782,246

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2016
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	Accounting Services – An entity related to a shareholder provided accounting and bookkeeping services of approximately $ 45,000 131,000 25,000 Office Lease - A non-employee director of the Company is also the CEO of The Doctors Laboratory (“TDL”). The Company leases its UK office space from TDL and has incurred expenses of approximately $ 142,000 10,000 Other – At December 31, 2015, there was a receivable balance in the amount of $ 10,366 0

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	Lease commitment – In March 2014, the Company entered into a lease agreement for offices in London which was amended January 1, 2016. The lease term commenced on December 1, 2014 and expires in March 2019. The lease can be cancelled early by either party upon 3 months’ notice The Company also has a five year lease for offices in the United States effective July 2014. The lease expires in August 2019 Future minimum lease payments under the Company’s operating leases are as follows at December 31, 2016: London United States 2017 $ 128,810 $ 312,909 2018 128,810 330,291 2019 25,970 225,297 $ 283,590 $ 868,497 For the years ended December 31, 2016 and December 31, 2015, the Company incurred rental expense in the amount of approximately $ 445,000 104,000

Earnings Per Share

Earnings Per Share	12 Months Ended
	Dec. 31, 2016
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	Basic earnings (loss) per Ordinary Share is computed by dividing net income (loss) available to ordinary shareholders by the weighted-average number of Ordinary Shares outstanding during the period. Diluted earnings (loss) per common share is computed by dividing net income (loss) available to ordinary shareholders by the sum of (1) the weighted-average number of Ordinary Shares outstanding during the period, (2) the dilutive effect of the assumed exercise of share options using the treasury stock method, and (3) the dilutive effect of other potentially dilutive securities. Years Ended December 31, Earnings per share 2016 2015 2014 Company posted Net loss Net loss Net loss Basic weighted average shares outstanding 1,177,693,383 852,088,530 85,515,588 Dilutive effect of Ordinary Share equivalents None None None Dilutive weighted average shares outstanding 1,177,693,383 852,088,530 85,515,588 For purposes of the diluted net loss per share calculation, share options and warrants are considered to be potentially dilutive securities and are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive. Therefore, basic and diluted net loss per share was the same for the periods presented due to the Company’s net loss position. The following table shows the number of share equivalents that were excluded from the computation of diluted earnings (loss) per share for the respective periods because the effect would have been anti-dilutive: Year Ended Year Ended Year Ended December 31, 2016 December 31, 2015 December 31, 2014 Total share options 79,372,198 61,362,198 - Total warrants-equity classified 1,782,246 1,782,246 - Total warrants-liability classified 5,806,280 5,806,280 - Total share options and warrants 86,960,724 68,950,724 -

Taxes

Taxes	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	Tax rates: The Company is incorporated in Great Britain. The effective corporate tax rate applying to a company that is incorporated in Great Britain on December 31, 2016 is 20 20.25 Tax assessment: The periods open to inquiry by the United Kingdom (“UK”) tax authorities are 2015 and 2016. The Company has not been issued final tax assessments since its establishment in Switzerland. Deferred taxes: Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Management currently believes that since the Company has a history of losses, it is more likely than not that the deferred tax assets relating to the loss carryforwards and other temporary differences will not be realized in the foreseeable future. Therefore, the Company provided a full valuation allowance to reduce the deferred tax assets. The main reconciling item between the statutory tax rate of the Company and the effective tax rate is the recognition of valuation allowances in respect of deferred taxes relating to accumulated net operating losses carried forward due to the uncertainty of the realization of such deferred taxes. At December 31, 2016 and 2015, there were no known uncertain tax positions. We have not identified any tax positions for which it is reasonably possible that a significant change will occur during the next 12 months. December 31, 2016 December 31, 2015 December 31, 2014 Domestic (UK) $ (17,956,167) $ (39,599,123) $ (332,663) Foreign (184,830) (5,718,409) (1,614,890) Loss before income tax $ (18,140,997) $ (45,317,532) $ (1,947,553) December 31, 2016 December 31, 2015 December 31, 2014 Current income taxes Domestic (UK) - - - Foreign - - - Deferred income taxes - - - Domestic (UK) - - - Foreign - - - Income tax expense/recovery December 31, 2016 December 31, 2015 (Revised) December 31, 2014 Net loss before income tax (18,140,997) (45,317,532) (1,947,553) Statutory rate 20.00 % 20.25 % 21.50 % Expected income tax recovery (3,628,199) (9,176,800) (418,724) Impact on income tax expense/recovery from Change in valuation allowance 1,336,161 7,447,002 572,139 Permanent differences – excess consideration - 3,904,864 - Permanent differences - liability related to options and warrants (130,061) (225,748) - Change of tax rate from prior year 80,986 15,596 - Tax rate difference in foreign jurisdictions 2,341,113 (1,964,914) (153,415) Income tax expense - - - December 31, 2016 December 31, 2015 (Revised) Deferred tax assets Stock-based compensation 994,618 210,573 Stock option and warrant revaluation 1,525,594 3,181,481 Tax loss carry forward 13,370,548 11,162,545 Valuation allowance (15,890,760) (14,554,599) Deferred tax assets/liabilities - - Pursuant to ASC 740-10-25-3 Income Taxes The following changes were made in this Note 11 to correct errors in prior periods: · At December 31, 2015, the Company’s deferred income tax asset for stock option and warrant revaluation was increased by $ 3.1 · the Company re-allocated the deferred tax assets among its various filing jurisdictions and the foreign tax rate differential was reduced accordingly. In 2016, as a result of a transfer pricing adjustment, the Company has re-allocated the deferred tax assets among its various filing jurisdictions. Due to the different statutory rates in effect in those jurisdictions, the total deferred tax asset has been reduced; however, because the Company continues to have a full valuation allowance against all of its deferred tax assets, this adjustment did not have an impact on its financial statements. Domestic Foreign 2017 - - 2018 - - 2019 - - 2020 - - 2021 - - Beyond 2021 38,399,914 21,785,348 Total operating loss carry forwards 38,399,914 21,785,348 At December 31, 2016, the Company had approximately $ 38.4 21.8 Research and development credits: The Company carries out extensive research and development activities, and may benefit from the UK research and development tax relief regime, whereby the Company can receive an enhanced UK tax deduction on its research and development activities. Where the Company is loss making for the period it can elect to surrender taxable losses for a refundable tax credit. The losses available to surrender are equal to the lower of the sum of the research and development qualifying expenditure and enhanced tax deduction and the Company’s taxable losses for the period with the tax credit for December 31, 2016 available at a rate of 14.5 Qualifying expenditures comprise of chemistry and manufacturing consumables, employment costs for research staff, clinical trials management and other subcontracted research expenditures. In August 2016, the Company filed a credit claim for 2015 tax year. The credit claim was in the amount of approximately $ 578,000

Segment Information

Segment Information	12 Months Ended
	Dec. 31, 2016
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	NOTE 12 – Segment Information The chief operating decision maker (“CODM”) is the Company’s CEO. Neither the CODM nor the Company’s directors receive disaggregated financial information about the locations in which research and development is occurring. Therefore, the Company considers that it has only one reporting segment. December 31, December 31, 2015 2015 United States $ 28,849 $ 32,373 United Kingdom 29,515 8,140 Total $ 58,364 $ 40,513

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2016
Subsequent Events [Abstract]
Subsequent Events [Text Block]	NOTE 13 – Subsequent Events The Company has evaluated events up to the filing date of these financial statements and determined that no subsequent event activity required disclosure.

Summary of Significant Accoun20

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of Consolidation – The Combined and Consolidated Financial Statements include the accounts of the Company, Volution and Volution Immuno Pharmaceuticals Ltd (a private limited company incorporated in England and Wales), its wholly-owned subsidiary, which was incorporated in London on August 22, 2014. On September 6, 2016, Volution Immuno Pharmaceuticals Ltd was dissolved. All intercompany transactions have been eliminated.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency – The functional currency of the Company is U.S. dollars as that is the primary economic environment in which the Company operates as well as the currency in which it has been financed. The reporting currency of the Company is U.S. Dollars. The Company translated its non-U.S. operations’ assets and liabilities denominated in foreign currencies into U.S. dollars at current rates of exchange as of the balance sheet date and income and expense items at the average exchange rate for the reporting period. Translation adjustments resulting from exchange rate fluctuations are recorded as foreign currency translation adjustments, a component of accumulated other comprehensive (loss) income. Gains or losses from foreign currency transactions are included in foreign currency exchange gains (losses).
Use of Estimates, Policy [Policy Text Block]	Use of Estimates – The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that may affect the reported amounts of assets, liabilities, equity, revenue, expenses and related disclosure of contingent assets and liabilities. Management’s estimates and judgments include assumptions used in the evaluation of impairment and useful lives of intangible assets (patents), accrued liabilities, deferred income taxes, liabilities related to stock options and warrants, stock-based compensation and various other assumptions that are believed to be reasonable under the circumstances. Actual results may differ from those estimates under different assumptions or conditions.
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements – The carrying amounts of financial instruments, including cash and cash equivalents, short-term investments, restricted cash, receivable from related party and accounts payable approximate fair value due to their short-term maturities. The Company’s liabilities related to options and warrants relate to equity and debt financing rounds and options related to RPC, and are recognized on the balance sheet at their fair value, with changes in the fair value accounted for in the Statements of Comprehensive Loss and included in changes in fair value of option/warrant liabilities.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents – The Company considers all highly-liquid investments with original maturities of 90 days or less at the time of acquisition to be cash equivalents. The Company had no cash equivalents as of December 31, 2016 and December 31, 2015.
Investment, Policy [Policy Text Block]	Short-term investments – Short-term investments consist of certificates of deposit that are expected to be converted into cash within one year.
Restricted deposit [Policy Text Block]	Restricted cash - Restricted cash is collateral for a letter of credit related to the Company’s office lease.
Prepaid Expenses and Other Current Assets [Policy Text Block]	Prepaid Expenses and Other Current Assets – Prepaid expenses and other current assets consist principally of VAT receivables and prepaid expenses.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and equipment, net – Property and equipment are stated at cost, net of accumulated depreciation. Years Computers, peripheral, and scientific equipment 3 Office furniture and equipment 3 Depreciation expense for the years ended December 31, 2016, 2015 and 2014 was $ 36,898 7,040 3,051
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Long-Lived Assets – The Company reviews all long-lived assets for impairment whenever events or circumstances indicate the carrying amount of such assets may not be recoverable. Recoverability of assets to be held or used is measured by comparison of the carrying value of the asset to the future undiscounted net cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment recognized is measured by the amount by which the carrying value of the asset exceeds the discounted future cash flows expected to be generated by the asset.
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	Patent Acquisition Costs – Patent acquisition costs and related capitalized legal fees are amortized on a straight-line basis over the shorter of the legal or economic life. The estimated useful life is 22
Accrued Expenses [Policy Text Block]	Accrued Expenses – As part of the process of preparing the Combined and Consolidated Financial Statements, it requires the estimate of accrued expenses. This process involves identifying services that third parties have performed on the Company’s behalf and estimating the level of service performed and the associated cost incurred on these services as of each balance sheet date in the Company’s Combined and Consolidated Financial Statements. Examples of estimated accrued expenses include contract service fees in conjunction with pre-clinical and clinical trials and professional service fees. In connection with these service fees, the Company estimates are most affected by its understanding of the status and timing of services provided relative to the actual services incurred by the service providers. In the event that the Company does not identify certain costs that have been incurred or it under or over-estimates the level of services or costs of such services, our reported expenses for a reporting period could be understated or overstated. The date on which certain services commence, the level of services performed on or before a given date, and the cost of services are often subject to our judgment. The Company makes these judgments based upon the facts and circumstances known to us in accordance with U.S. GAAP.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Expenses – Costs associated with research and development are expensed as incurred. Research and development expenses include, among other costs, personnel expenses, costs incurred by outside laboratories, manufacturers’ and other accredited facilities in connection with clinical trials and preclinical studies. Research and development expense for the years ended December 31, 2016, 2015 and 2014 was $ 17,306,001 5,799,076 1,616,204 577,671
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation Expense – Stock-based compensation expense is recorded using the fair-value based method for all awards granted. Compensation costs for stock options and awards is recorded in earnings (loss) over the requisite service period based on the fair value of those options and awards. For employees, fair value is estimated at the grant date and for non-employees fair value is re-measured at each reporting date as required by ASC 718, “Compensation-Stock Compensation,” and ASC 505-50, “Equity-Based Payments to Non-Employees.” Fair values of awards granted under the share option plans are estimated using a Black-Scholes option pricing model. The determination of fair value for stock-based awards on the date of grant using an option pricing model requires management to make certain assumptions regarding a number of complex and subjective variables. The Company classifies its stock-based payments as either liability-classified awards or as equity-classified awards. The Company remeasures liability-classified awards to fair value at each balance sheet date until the award is settled. The liability for liability-classified awards generally is equal to the fair value of the award as of the balance sheet date multiplied by the percentage vested at the time. The Company charges (or credits) the change in the liability amount from one balance sheet date to another to changes in fair value of option/warrant liabilities.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk – Financial instruments that subject the Company to credit risk consist of cash and cash equivalents. The Company maintains cash and cash equivalents with well-capitalized financial institutions. At times, those amounts may exceed insured limits. The Company has no significant concentrations of credit risk.
Income Tax, Policy [Policy Text Block]	Income Taxes – The Company accounts for income taxes in accordance with the accounting rules that require an asset and liability approach to accounting for income taxes based upon the future expected values of the related assets and liabilities. Deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and for tax loss and credit carry forwards, and are measured using the expected tax rates estimated to be in effect when such basis differences reverse. Valuation allowances are established, if necessary, to reduce the deferred tax asset to the amount that will, more likely than not, be realized.
Income Tax Uncertainties, Policy [Policy Text Block]	Uncertain Tax Positions – The Company follows the provisions of ASC 740 “ Accounting for Uncertainty in Income Taxes Accounting for Uncertainty in Income Taxes
Earnings Per Share, Policy [Policy Text Block]	Earnings (Loss) Per Share – Basic earnings (loss) per common share is computed by dividing net income (loss) available to common shareholders by the weighted-average number of Ordinary Shares outstanding during the period. Diluted earnings (loss) per common share is computed by dividing net income (loss) available to common shareholders by the sum of (1) the weighted-average number of Ordinary Shares outstanding during the period, (2) the dilutive effect of the assumed exercise of options and warrants using the treasury stock method and (3) the dilutive effect of other potentially dilutive securities.
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Income (Loss) – Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. The Company’s other comprehensive income (loss) is comprised of foreign currency translation adjustments. Balance January 1, 2014 $ (33,357) Net current period other comprehensive income 79,438 Balance December 31, 2014 46,081 Net current period other comprehensive income 110,399 Balance December 31, 2015 156,480 Net current period other comprehensive loss (436,577) Balance December 31, 2016 $ (280,097)
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers” (“ASU 2014-09”), which supersedes nearly all existing revenue recognition guidance under GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing GAAP. On July 9, 2015, the FASB voted to defer the effective date by one year to December 15, 2017 for interim and annual reporting periods beginning after that date. Early adoption of ASU 2014-09 is permitted but not before the original effective date (annual periods beginning after December 15, 2016). When effective, ASU 2014-09 prescribes either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients; or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). The Company does not believe the adoption of this standard will have a material impact on our financial position, results of operations or related financial statement disclosures. In February 2016, the FASB issued ASU No. 2016-02, Leases In March 2016, the FASB issued ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting In August 2016, the FASB issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments In October 2016, the FASB issued ASU 2016-16, Intra-Entity Transfers of Assets Other Than Inventory In November 2016, the FASB issued ASU, 2016-18, Restricted Cash cash flows from investing activities and to certain beginning and ending cash and cash equivalent totals shown on Combined and Consolidated Statement of Cash Flows. The Company does not believe the adoption of this standard will have a material impact on its financial position, results of operations or related financial statement disclosures.

Summary of Significant Accoun21

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2016
Significant Accounting Policies [Line Items]
Schedule of Rate of Depreciation of Property, Plant and Equipment [Table Text Block]	Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates: Years Computers, peripheral, and scientific equipment 3 Office furniture and equipment 3
Comprehensive Income (Loss) [Table Text Block]	The following table provides details with respect to changes in accumulated other comprehensive income (loss) (AOCI), which is comprised of foreign currency translation adjustments, as presented in the balance sheets at December 31, 2016 and 2015: Balance January 1, 2014 $ (33,357) Net current period other comprehensive income 79,438 Balance December 31, 2014 46,081 Net current period other comprehensive income 110,399 Balance December 31, 2015 156,480 Net current period other comprehensive loss (436,577) Balance December 31, 2016 $ (280,097)

Reverse Acquisition (Tables)

Reverse Acquisition (Tables)	12 Months Ended
	Dec. 31, 2016
Business Combinations [Abstract]
Schedule of Business Combination Purchase Price Allocation [Table Text Block]	The purchase price for Celsus on September 18, 2015, the closing date of the Acquisition, was as follows: Fair value of Celsus Ordinary Shares outstanding $ 20,034,625 (a) Fair value of Celsus share options 277,461 (2,516,690 options) Fair value of Celsus warrants 27,054 (1,782,246 warrants) Total purchase price $ 20,339,140 (a) computed by multiplying 55,636,283 0.3601
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	The following table summarizes the allocation of the purchase consideration to the assets acquired and liabilities assumed based on their fair values at September 18, 2015: Cash and cash equivalents $ 1,410,577 Restricted cash 142,079 Prepaid expenses and other assets acquired 1,672,028 Excess consideration 19,283,280 Liabilities related to options and warrants (1,800,154) Other assumed liabilities (368,670) $ 20,339,140

Patent Acquisition Costs (Table

Patent Acquisition Costs (Tables)	12 Months Ended
	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets [Table Text Block]	Patent acquisition costs, net, are the asset costs of purchased patents and are amortized over the useful life of the patent determined to be 22 December 31, December 31, 2016 2015 Patent acquisition and related costs $ 92,434 $ 95,050 Less: Accumulated amortization (53,069) (42,567) $ 39,365 $ 52,483
Finite-lived Intangible Assets Amortization Expense [Table Text Block]	Approximate amortization expense of patent acquisition costs for the next five years is as follows: Year Ended Amount 2017 $ 2,944 2018 2,944 2019 2,944 2020 2,944 2021 2,944 Thereafter 24,645 $ 39,365

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2016
Class of Stock [Line Items]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. December 31, 2016 December 31, 2015 Carrying Fair Carrying Fair Fair Amount Value Amount Value Value $ $ $ $ Levels Liability related to RPC options 7,627,970 7,627,970 15,711,017 15,711,017 3 Liability related to warrants 34,838 34,838 685,141 685,141 3
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]	Some of the issued warrants contain non-standard anti-dilution terms and accordingly are recorded as liabilities. December 31, 2016 December 31, 2015 Carrying Fair Carrying Fair Fair Amount Value Amount Value Value $ $ $ $ Levels Reference Cash and cash equivalents 34,098,812 34,098,812 68,919,995 68,919,995 1 Note 2 Short-term investment 10,021,963 10,021,963 - - 1 Note 2 Restricted cash 142,168 142,168 142,079 142,079 1 Note 2 Accounts payable 2,214,313 2,214,313 4,320,588 4,320,588 1 - Liability related to options and warrants 7,662,808 7,662,808 16,396,158 16,396,158 3 Note 6
Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]	The Company’s financial assets and liabilities measured at fair value on a recurring basis, consisted of the following instruments as of the following dates: December 31, December 31, 2016 2015 Fair value measurements using input type Level 3 Warrants $ 34,838 $ 685,141 RPC options 7,627,970 15,711,017 Liabilities related to stock options and warrants $ 7,662,808 $ 16,396,158
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Fair value measurements using significant unobservable inputs (Level 3): Fair value of liabilities related to stock options and warrants Balance at December 31, 2014 $ - Balance at September 18, 2015 (Acquisition) 1,800,154 Changes in values of liabilities related to options and warrants (11,408,231) Value of liability related to options - transfer in 26,004,235 Balance at December 31, 2015 16,396,158 Changes in values of liabilities related to options and warrants (8,733,350) Balance at December 31, 2016 $ 7,662,808
Warrant [Member]
Class of Stock [Line Items]
Fair Value, by Balance Sheet Grouping [Table Text Block]	Fair values were estimated using the following assumptions for the warrants: December 31, 2016 2015 Expected dividend yield 0 % 0 % Expected volatility 73.39 % 233.0 % Risk-free interest 0.51 % 0.75 % Expected life 0.26 years 1.26 years

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2016
Stockholders' Equity Note [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	The following is a summary of the Company’s share option activity and related information for employees and directors for the year ended December 31, 2016: Weighted average Weighted Weighted remaining average average contractual Aggregate Number exercise grant date term intrinsic of shares price fair value (in years) value Options outstanding as of January 1, 2016 61,362,198 $ 0.34 9.7 $ - Changes during the period: Granted 22,700,000 $ 0.14 $ 0.09 Forfeited (4,690,000) $ 0.21 $ 0.12 Options outstanding at December 31, 2016 79,372,198 $ 0.29 8.7 $ - Exercisable options at December 31, 2016 25,486,486 $ 0.34 8.7 $ -
Schedule of Nonvested Share Activity [Table Text Block]	The following is a summary of the Company’s non-vested share options at December 31, 2016 and changes during the year ended December 31, 2016: Weighted average Number grant date of shares fair value Non-vested options at December 31, 2015 58,480,181 $ 0.21 Options granted 22,700,000 $ 0.09 Options vested (22,604,469) $ 0.18 Non-vested options forfeited (4,690,000) $ 0.12 Non-vested at December 31, 2016 53,885,712 $ 0.24
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	December 31, 2016 2015 2014 Expected dividend yield 0 % 0 % - Expected volatility 74.18%-80.71% 71.28%-81.79% - Risk-free interest 1.03%-1.52% 1.51%-2.27% - Expected life 5.5-6.25 years 5.5-10 years -
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	The following is a summary of the Company’s share options granted separated into ranges of exercise price: Remaining Options Weighted Options contractual outstanding average Weighted exercisable life (years Weighted Exercise at remaining average at for average price December contractual exercise December exercisable exercise (range) ($) 31, 2016 life (years) price ($) 31, 2016 options) price ($) 0.08-0.19 24,313,351 9.31 0.15 6,950,054 9.22 0.15 0.32 53,597,347 8.72 0.32 17,239,932 8.72 0.32 0.60-0.75 290,000 7.20 0.72 290,000 7.20 0.72 0.98-1.56 311,500 3.24 1.31 311,500 3.24 1.31 2.00 860,000 6.73 2.00 695,000 6.73 2.00 79,372,198 25,486,486
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	The warrants outstanding at December 31, 2016, classified as equity, were issued in connection with several private placements of the Company are as follows: Number of Exercise Grant date warrants Price Expiration date 2012 warrants 1,383,086 $ 1.72 - $2.25 January 16, 2017-November 30, 2017 2013 warrants 399,160 $ 2.00 January 16, 2018-September 17, 2018 1,782,246

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Future minimum lease payments under the Company’s operating leases are as follows at December 31, 2016: London United States 2017 $ 128,810 $ 312,909 2018 128,810 330,291 2019 25,970 225,297 $ 283,590 $ 868,497

Earnings Per Share (Tables)

Earnings Per Share (Tables)	12 Months Ended
	Dec. 31, 2016
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Years Ended December 31, Earnings per share 2016 2015 2014 Company posted Net loss Net loss Net loss Basic weighted average shares outstanding 1,177,693,383 852,088,530 85,515,588 Dilutive effect of Ordinary Share equivalents None None None Dilutive weighted average shares outstanding 1,177,693,383 852,088,530 85,515,588
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Year Ended Year Ended Year Ended December 31, 2016 December 31, 2015 December 31, 2014 Total share options 79,372,198 61,362,198 - Total warrants-equity classified 1,782,246 1,782,246 - Total warrants-liability classified 5,806,280 5,806,280 - Total share options and warrants 86,960,724 68,950,724 -

Taxes (Tables)

Taxes (Tables)	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]	The components of loss before income taxes are as follows: December 31, 2016 December 31, 2015 December 31, 2014 Domestic (UK) $ (17,956,167) $ (39,599,123) $ (332,663) Foreign (184,830) (5,718,409) (1,614,890) Loss before income tax $ (18,140,997) $ (45,317,532) $ (1,947,553)
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	Income taxes relating to the Company’s operations are as follows: December 31, 2016 December 31, 2015 December 31, 2014 Current income taxes Domestic (UK) - - - Foreign - - - Deferred income taxes - - - Domestic (UK) - - - Foreign - - - Income tax expense/recovery
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Income taxes at the UK statutory rate compared to the Company’s income tax expenses as reported are as follows: December 31, 2016 December 31, 2015 (Revised) December 31, 2014 Net loss before income tax (18,140,997) (45,317,532) (1,947,553) Statutory rate 20.00 % 20.25 % 21.50 % Expected income tax recovery (3,628,199) (9,176,800) (418,724) Impact on income tax expense/recovery from Change in valuation allowance 1,336,161 7,447,002 572,139 Permanent differences – excess consideration - 3,904,864 - Permanent differences - liability related to options and warrants (130,061) (225,748) - Change of tax rate from prior year 80,986 15,596 - Tax rate difference in foreign jurisdictions 2,341,113 (1,964,914) (153,415) Income tax expense - - -
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	The Company’s deferred tax assets and liabilities consist of the following: December 31, 2016 December 31, 2015 (Revised) Deferred tax assets Stock-based compensation 994,618 210,573 Stock option and warrant revaluation 1,525,594 3,181,481 Tax loss carry forward 13,370,548 11,162,545 Valuation allowance (15,890,760) (14,554,599) Deferred tax assets/liabilities - -
Summary of Operating Loss Carryforwards [Table Text Block]	The Company’s operating loss carry forward of all jurisdictions expire according to the following schedule: Domestic Foreign 2017 - - 2018 - - 2019 - - 2020 - - 2021 - - Beyond 2021 38,399,914 21,785,348 Total operating loss carry forwards 38,399,914 21,785,348

Segment Information (Tables)

Segment Information (Tables)	12 Months Ended
	Dec. 31, 2016
Segment Reporting [Abstract]
Long-lived Assets by Geographic Areas [Table Text Block]	The following table presents the Company’s tangible fixed assets by geographic region: December 31, December 31, 2015 2015 United States $ 28,849 $ 32,373 United Kingdom 29,515 8,140 Total $ 58,364 $ 40,513

Nature of Business (Details Tex

Nature of Business (Details Textual)	1 Months Ended			12 Months Ended
	Sep. 18, 2015USD ($)$ / sharesshares	Oct. 23, 2013USD ($)	Oct. 23, 2013GBP (£)	Dec. 31, 2016USD ($)shares	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Sep. 18, 2015£ / shares
Nature Of Business [Line Items]
American Depositary Shares Description				each representing 100
Percentage Of Total Shares Issued	92.85%						92.85%
Percentage Of Total Shares Issued On Diluted Basis	91.68%						91.68%
Business Combination Share Exchange				721:1
Stock Issued During Period, Value, New Issues					$ 69,574,354
Payments of Stock Issuance Costs				$ 0	$ 5,425,646	$ 0
Proceeds from Issuance of Private Placement	$ 69,600,000
Private Placement [Member]
Nature Of Business [Line Items]
Stock Issued During Period, Shares, New Issues | shares	395,881,100
Stock Issued During Period, Value, New Issues	$ 75,000,000
Sale of Stock, Price Per Share | $ / shares	$ 0.18945
Sale of Stock, Percentage of Ownership after Transaction	33.30%
Payments of Stock Issuance Costs	$ 5,400,000
Private Placement [Member] | American Depositary Share [Member]
Nature Of Business [Line Items]
Stock Issued During Period, Shares, New Issues | shares	3,958,811
Sale of Stock, Price Per Share | $ / shares	$ 18.945
RPC Pharma Limited [Member]
Nature Of Business [Line Items]
Shares Issued, Price Per Share | £ / shares							£ 0.01
Stock Issued During Period, Shares, Acquisitions | shares	55,636,283			722,345,600
Volution [Member] | Patents [Member]
Nature Of Business [Line Items]
Payments to Acquire Intangible Assets		$ 107,000	£ 65,000

Summary of Significant Accoun31

Summary of Significant Accounting Policies (Details)	12 Months Ended
	Dec. 31, 2016
Computers, peripheral, and scientific equipment [Member]
Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Office furniture and equipment [Member]
Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life	3 years

Summary of Significant Accoun32

Summary of Significant Accounting Policies (Details 1) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Significant Accounting Policies [Line Items]
Beginning Balance	$ 156,480	$ 46,081	$ (33,357)
Net current period other comprehensive income (loss)	(436,577)	110,399	79,438
Ending Balance	$ (280,097)	$ 156,480	$ 46,081

Summary of Significant Accoun33

Summary of Significant Accounting Policies (Details Textual) - USD ($)	1 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Significant Accounting Policies [Line Items]
Research and Development Expense		$ 17,306,001	$ 5,799,076	$ 1,616,204
Depreciation		$ 36,898	$ 7,040	$ 3,051
Research and Development Expense [Member]
Significant Accounting Policies [Line Items]
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount	$ 577,671
Patents [Member]
Significant Accounting Policies [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period		22 years

Reverse Acquisition (Details)

Reverse Acquisition (Details)	1 Months Ended
	Sep. 18, 2015USD ($)shares
Business Combination [Line Items]
Total purchase price	$ 20,339,140
Options | shares	2,516,690
Warrants | shares	1,782,246
Fair value of Celsus share options [Member]
Business Combination [Line Items]
Total purchase price	$ 277,461
Fair value of Celsus Ordinary Shares outstanding [Member]
Business Combination [Line Items]
Total purchase price	20,034,625	[1]
Fair value of Celsus warrants [Member]
Business Combination [Line Items]
Total purchase price	$ 27,054
[1]	computed by multiplying 55,636,283 Ordinary Shares of Celsus at Acquisition by the closing stock price on September 18, 2015, of $0.3601.

Reverse Acquisition (Details 1)

Reverse Acquisition (Details 1)	Sep. 18, 2015USD ($)
Business Combination [Line Items]
Cash and cash equivalents	$ 1,410,577
Restricted cash	142,079
Prepaid expenses and other assets acquired	1,672,028
Excess consideration	19,283,280
Liabilities related to options and warrants	(1,800,154)
Other assumed liabilities	(368,670)
Total	$ 20,339,140

Reverse Acquisition (Details Te

Reverse Acquisition (Details Textual) - $ / shares	1 Months Ended	12 Months Ended
	Sep. 18, 2015	Dec. 31, 2016	Dec. 31, 2015
Business Combination [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired		91.68%
Common Stock, Shares, Outstanding		1,177,693,383	1,177,693,383
RPC Pharma Limited [Member]
Business Combination [Line Items]
Stock Issued During Period, Shares, Acquisitions	55,636,283	722,345,600
Celcus [Member]
Business Combination [Line Items]
Common Stock, Shares, Outstanding	55,636,283
Business Acquisition, Share Price	$ 0.3601

Patent Acquisition Costs (Detai

Patent Acquisition Costs (Details) - Patents [Member] - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Patent acquisition and related costs	$ 92,434	$ 95,050
Less: Accumulated amortization	(53,069)	(42,567)
Patent Acquisition Costs, Net	$ 39,365	$ 52,483

Patent Acquisition Costs (Det38

Patent Acquisition Costs (Details 1) - Patents [Member] - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]
2,017	$ 2,944
2,018	2,944
2,019	2,944
2,020	2,944
2,021	2,944
Thereafter	24,645
Patent Acquisition Costs, Net	$ 39,365	$ 52,483

Patent Acquisition Costs (Det39

Patent Acquisition Costs (Details Textual) - Patents [Member] - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	22 years	22 years
Amortization of Intangible Assets	$ 3,046	$ 3,122	$ 1,891

Loans Payable - Shareholders (D

Loans Payable - Shareholders (Details Textual) - USD ($)	1 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Jun. 30, 2015	Jun. 22, 2015
Interest Expense, Debt			$ 3,000,000
Liability Related To Stock Options and Warrants		$ 7,662,808	16,396,158
Interest Expense, Total		0	3,053,948	$ 5,436
Financing Interest Expense	$ 23,000,000		23,000,000
Shareholder [Member]
Interest Expense, Total		$ 0	3,053,948	$ 5,436
RPC Pharma Ltd [Member]
Short-term Debt, Total					$ 3,000,000	$ 3,000,000
Percentage Of Shares Outstanding					15.00%	15.00%
Liability Related To Stock Options and Warrants	$ 26,000,000		$ 26,000,000
Stockholders' Equity Attributable to Noncontrolling Interest						$ 26,000,000
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners					15.00%	15.00%

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Liabilities	$ 11,771,128	$ 21,174,037
Fair Value, Inputs, Level 3 [Member] | Liability related to RPC options [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial Liabilities Fair Value Disclosure	7,627,970	15,711,017
Liabilities	7,627,970	15,711,017
Fair Value, Inputs, Level 3 [Member] | Liability related to warrants [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial Liabilities Fair Value Disclosure	34,838	685,141
Liabilities	$ 34,838	$ 685,141

Fair Value Measurements (Deta42

Fair Value Measurements (Details 1) - USD ($)	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and cash equivalents	$ 34,098,812	$ 68,919,995	$ 3,327,468	$ 553,654
Short-term investments	10,021,963	0
Restricted cash	142,168	142,079
Accounts payable	2,214,313	4,320,588
Liability related to options and warrants	7,662,808	16,396,158
Fair Value, Inputs, Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Short-term investments	10,021,963	0
Cash and cash equivalents	34,098,812	68,919,995
Restricted cash	142,168	142,079
Accounts payable	2,214,313	4,320,588
Fair Value, Inputs, Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Liability related to options and warrants	$ 7,662,808	$ 16,396,158

Fair Value Measurements (Deta43

Fair Value Measurements (Details 2) - Employee Stock Option [Member]	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Class of Stock [Line Items]
Expected dividend yield	0.00%	0.00%
Expected volatility	73.39%	233.00%
Risk-free interest	0.51%	0.75%
Expected life	3 months 4 days	1 year 3 months 4 days

Fair Value Measurements (Deta44

Fair Value Measurements (Details 3) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Stock Options And Warrants Fair Value Disclosure	$ 7,627,970
RPC Pharma Ltd [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Stock Options And Warrants Fair Value Disclosure	8,083,047	$ 15,711,017
Fair Value, Inputs, Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Stock Options And Warrants Fair Value Disclosure	7,662,808	16,396,158
Fair Value, Inputs, Level 3 [Member] | Warrant [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Stock Options And Warrants Fair Value Disclosure	34,838	685,141
Fair Value, Inputs, Level 3 [Member] | RPC Pharma Ltd [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Stock Options And Warrants Fair Value Disclosure	$ 7,627,970	$ 15,711,017

Fair Value Measurements (Deta45

Fair Value Measurements (Details 4) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Changes in values of liabilities related to options and warrants	$ (8,733,350)	$ (11,408,231)	$ 0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Balance	16,396,158	0
Balance at September 18, 2015 (Acquisition)		1,800,154
Changes in values of liabilities related to options and warrants	(8,733,350)	(11,408,231)
Value of liability related to stock options - transfer in		26,004,235
Balance	$ 7,662,808	$ 16,396,158	$ 0

Fair Value Measurements (Deta46

Fair Value Measurements (Details Textual) - USD ($)	1 Months Ended			12 Months Ended
	Sep. 30, 2015	Sep. 18, 2015	Jun. 30, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Jun. 22, 2015
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award		5,617,977
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.18945
Warrant Issuance Exercise Price Description				share or warrant issuance at less than $0.1958 price share or exercise price per share
Liability Related To Stock Options and Warrants				$ 7,662,808	$ 16,396,158
Stock Options And Warrants Fair Value Disclosure				7,627,970
Debt Instrument, Unamortized Discount	$ 3,000,000
Interest Expense, Other	3,000,000
Financing Interest Expense	23,000,000				$ 23,000,000
Derivative Liability, Fair Value, Gross Liability		$ 650,303		$ 34,838
Stock Issued During Period, Shares, For Exercised Of Warrant		188,303
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount				86,960,724	68,950,724	0
Warrant [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		5,806,280
RPC Pharma Ltd [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Percentage Of Shares Outstanding			15.00%				15.00%
Liability Related To Stock Options and Warrants	$ 26,000,000				$ 26,000,000
Stock Options And Warrants Fair Value Disclosure				$ 8,083,047	$ 15,711,017
Short-term Debt			$ 3,000,000				$ 3,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value			$ 26,000,000
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners			15.00%				15.00%

Shareholders' Equity (Details)

Shareholders' Equity (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Class of Stock [Line Items]
Number of shares, Options outstanding at end of the period	79,372,198
Number of shares, Options exercisable at end of the period	25,486,486
Employee Stock Option [Member]
Class of Stock [Line Items]
Number of shares, Outstanding at beginning of the period	61,362,198
Number of shares, Granted	22,700,000
Number of shares, Forfeited	(4,690,000)
Number of shares, Options outstanding at end of the period	79,372,198	61,362,198
Number of shares, Options exercisable at end of the period	25,486,486
Weighted average exercise price, Outstanding at beginning of the period	$ 0.34
Weighted average exercise price, Granted	0.14
Weighted average exercise price, Forfeited	0.21
Weighted average exercise price,outstanding at end of the period	0.29	$ 0.34
Options exercisable at end of the period, Weighted average exercise price	0.34
Weighted average grant date fair value Granted	0.09
Weighted average grant date fair value Forfeited	$ 0.12
Weighted average remaining contractual term, Options outstanding during the period (in years)	8 years 8 months 12 days
Weighted average remaining contractual term, Options exercisable at end of the period (in years)	8 years 8 months 12 days	9 years 8 months 12 days
Aggregate intrinsic value, Options outstanding at beginning of the period		$ 0
Aggregate intrinsic value, Options outstanding at end of the period	$ 0
Aggregate intrinsic value, Options exercisable at end of the period	$ 0

Shareholders' Equity (Details 1

Shareholders' Equity (Details 1) - $ / shares	1 Months Ended	12 Months Ended
	Sep. 18, 2015	Dec. 31, 2016
Number of Shares
Non-vested options Vested	(2,516,690)
Employee Stock Option [Member]
Number of Shares
Non-vested options granted		22,700,000
Non-vested options Vested		(22,604,469)
Non-vested options forfeited		(4,690,000)
Weighted average grant date fair value
Non-vested options granted		$ 0.09
Non-vested options Vested		0.18
Non-vested options forfeited		$ 0.12
Nonvested Option [Member]
Number of Shares
Non-vested options at December 31, 2015		58,480,181
Non-vested at December 31, 2016		53,885,712
Weighted average grant date fair value
Non-vested options at December 31, 2015		$ 0.21
Non-vested at December 31, 2016		$ 0.24

Shareholders' Equity (Details 2

Shareholders' Equity (Details 2) - Call Option [Member]	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Class of Stock [Line Items]
Expected dividend yield	0.00%	0.00%	0.00%
Expected volatility			0.00%
Risk-free interest			0.00%
Minimum [Member]
Class of Stock [Line Items]
Expected volatility	74.18%	71.28%
Risk-free interest	1.03%	1.51%
Expected life	5 years 6 months	5 years 6 months
Maximum [Member]
Class of Stock [Line Items]
Expected volatility	80.71%	81.79%
Risk-free interest	1.52%	2.27%
Expected life	6 years 3 months	10 years

Shareholders' Equity (Details 3

Shareholders' Equity (Details 3)	12 Months Ended
	Dec. 31, 2016$ / sharesshares
Class of Stock [Line Items]
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Number | shares	79,372,198
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Number | shares	25,486,486
Exercise Price Range One [Member]
Class of Stock [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	$ 0.08
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	$ 0.19
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Number | shares	24,313,351
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	9 years 3 months 22 days
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 0.15
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Number | shares	6,950,054
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	9 years 2 months 19 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 0.15
Exercise Price Range Two [Member]
Class of Stock [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	$ 0.32
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Number | shares	53,597,347
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	8 years 8 months 19 days
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 0.32
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Number | shares	17,239,932
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	8 years 8 months 19 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 0.32
Exercise Price Range Three [Member]
Class of Stock [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	0.60
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	$ 0.75
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Number | shares	290,000
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	7 years 2 months 12 days
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 0.72
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Number | shares	290,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	7 years 2 months 12 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 0.72
Exercise Price Range Four [Member]
Class of Stock [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	0.98
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	$ 1.56
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Number | shares	311,500
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	3 years 2 months 26 days
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 1.31
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Number | shares	311,500
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	3 years 2 months 26 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 1.31
Exercise Price Range Five [Member]
Class of Stock [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	$ 2
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Number | shares	860,000
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	6 years 8 months 23 days
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 2
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Number | shares	695,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	6 years 8 months 23 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 2

Shareholders' Equity (Details 4

Shareholders' Equity (Details 4) - $ / shares	12 Months Ended
	Dec. 31, 2016	Sep. 18, 2015
Class of Stock [Line Items]
Grant date	1,782,246
Number of warrants		1,782,246
Exercise Price		$ 0.18945
Warrants 2012 [Member]
Class of Stock [Line Items]
Number of warrants	1,383,086
Warrants 2012 [Member] | Maximum [Member]
Class of Stock [Line Items]
Exercise Price	$ 2.25
Expiration date	Nov. 30, 2017
Warrants 2012 [Member] | Minimum [Member]
Class of Stock [Line Items]
Exercise Price	$ 1.72
Expiration date	Jan. 16, 2017
Warrants 2013 [Member]
Class of Stock [Line Items]
Number of warrants	399,160
Exercise Price	$ 2
Warrants 2013 [Member] | Maximum [Member]
Class of Stock [Line Items]
Expiration date	Sep. 17, 2018
Warrants 2013 [Member] | Minimum [Member]
Class of Stock [Line Items]
Expiration date	Jan. 16, 2018

Shareholders' Equity (Details T

Shareholders' Equity (Details Textual) - USD ($)	Oct. 13, 2016	Jun. 29, 2016	Apr. 22, 2016	Mar. 23, 2016	Sep. 18, 2015	Dec. 31, 2016	Dec. 31, 2015	Jul. 29, 2016
Class of Stock [Line Items]
Stock Issued During Period, Value, New Issues							$ 69,574,354
Stock Issued During Period, Value, Issued For Services							$ 750,000
Common Stock, Shares Authorized						5,000,000,000	5,000,000,000
Common Stock, Shares, Outstanding						1,177,693,383	1,177,693,383
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares					2,516,690
Resigning Director [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	1,300,000
Weighted average exercise price, Granted	$ 0.080621
Non Employee [Member]
Class of Stock [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized						$ 8,957,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition						2 years 8 months 12 days
Employees And Directors [Member]
Class of Stock [Line Items]
Stock Issued During Period, Value, Share-based Compensation, Gross						$ 3,933,000
Director [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	1,300,000	7,800,000	1,300,000
Weighted average exercise price, Granted	$ 0.080621	$ 0.145	$ 0.18
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares		6,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Beginning Balance								1,300,000
Private Placement [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues					395,881,100
Stock Issued During Period, Value, New Issues					$ 75,000,000
Sale of Stock, Price Per Share					$ 0.18945
Employee Stock [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				11,000,000
Weighted average exercise price, Granted				$ 0.141
RPC Pharma Limited [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Acquisitions					55,636,283	722,345,600
MTS Health Partners [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Issued For Services					3,830,400
Stock Issued During Period, Value, Issued For Services					$ 750,000
Business Combination, Integration Related Costs					$ 500,000
2014 Equity Incentive Plan [Member]
Class of Stock [Line Items]
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period						141,142,420
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized						61,770,222

Related Party Transactions (Det

Related Party Transactions (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Related Party Transaction [Line Items]
Related Party Transaction, Amounts of Transaction	$ 45,000	$ 131,000	$ 25,000
Accounts Receivable, Related Parties, Current	0	10,366
The Doctors Laboratory [Member]
Related Party Transaction [Line Items]
Operating Leases, Rent Expense	$ 142,000	$ 10,000

Commitments and Contingencies54

Commitments and Contingencies (Details)	Dec. 31, 2016USD ($)
London [Member]
Commitments And Contingent Liabilities [Line Items]
2,017	$ 128,810
2,018	128,810
2,019	25,970
Total	283,590
United States [Member]
Commitments And Contingent Liabilities [Line Items]
2,017	312,909
2,018	330,291
2,019	225,297
Total	$ 868,497

Commitments and Contingencies55

Commitments and Contingencies (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Commitments And Contingent Liabilities [Line Items]
Operating Leases, Rent Expense, Net, Total	$ 445,000	$ 104,000
London [Member]
Commitments And Contingent Liabilities [Line Items]
Description of Lessor Leasing Arrangements, Operating Leases	In March 2014, the Company entered into a lease agreement for offices in London which was amended January 1, 2016. The lease term commenced on December 1, 2014 and expires in March 2019. The lease can be cancelled early by either party upon 3 months notice
United States [Member]
Commitments And Contingent Liabilities [Line Items]
Description of Lessor Leasing Arrangements, Operating Leases	The Company also has a five year lease for offices in the United States effective July 2014. The lease expires in August 2019

Earnings Per Share (Details)

Earnings Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Earnings Per Share [Line Items]
Basic weighted average shares outstanding	1,177,693,383	852,088,530	85,515,588
Dilutive weighted average shares outstanding	1,177,693,383	852,088,530	85,515,588

Earnings Per Share (Details 1)

Earnings Per Share (Details 1) - shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Earnings Per Share [Line Items]
Total stock options and warrants	86,960,724	68,950,724	0
Stock Options [Member]
Earnings Per Share [Line Items]
Total stock options and warrants	79,372,198	61,362,198	0
Warrants Equity Classified [Member]
Earnings Per Share [Line Items]
Total stock options and warrants	1,782,246	1,782,246	0
Warrants Liability Classified [Member]
Earnings Per Share [Line Items]
Total stock options and warrants	5,806,280	5,806,280	0

Taxes (Details)

Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Operating Loss Carryforwards [Line Items]
Domestic (UK)	$ (17,956,167)	$ (39,599,123)	$ (332,663)
Foreign	(184,830)	(5,718,409)	(1,614,890)
Loss before income tax	$ (18,140,997)	$ (45,317,532)	$ (1,947,553)

Taxes (Details 1)

Taxes (Details 1) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Current income taxes
Domestic (UK)	$ 0	$ 0	$ 0
Foreign	0	0	0
Deferred income taxes
Domestic (UK)	0	0	0
Foreign	0	0	0
Income tax expense/recovery	$ 0	$ 0	$ 0

Taxes (Details 2)

Taxes (Details 2) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Operating Loss Carryforwards [Line Items]
Net loss before income tax	$ (18,140,997)	$ (45,317,532)	$ (1,947,553)
Statutory rate	20.00%	20.25%	21.50%
Expected income tax recovery	$ (3,628,199)	$ (9,176,800)	$ (418,724)
Impact on income tax expense/recovery from
Change in valuation allowance	1,336,161	7,447,002	572,139
Permanent differences - excess consideration	0	3,904,864	0
Permanent differences - liability related to options and warrants	(130,061)	(225,748)	0
Change of tax rate from prior year	80,986	15,596	0
Tax rate difference in foreign jurisdictions	2,341,113	(1,964,914)	(153,415)
Income tax expense	$ 0	$ 0	$ 0

Taxes (Details 3)

Taxes (Details 3) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Deferred tax assets
Stock-based compensation	$ 994,618	$ 210,573
Stock option and warrant revaluation	1,525,594	3,181,481
Tax loss carry forward	13,370,548	11,162,545
Valuation allowance	(15,890,760)	(14,554,599)
Deferred tax assets/liabilities	$ 0	$ 0

Taxes (Details 4)

Taxes (Details 4)	Dec. 31, 2016USD ($)
Domestic Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
2,017	$ 0
2,018	0
2,019	0
2,020	0
2,021	0
Beyond 2,021	38,399,914
Total operating loss carry forwards	38,399,914
Foreign Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
2,017	0
2,018	0
2,019	0
2,020	0
2,021	0
Beyond 2,021	21,785,348
Total operating loss carry forwards	$ 21,785,348

Taxes (Details Textual)

Taxes (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Operating Loss Carryforwards [Line Items]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	20.00%	20.25%	21.50%
Effective Income Tax Rate Reconciliation, Tax Credit, Amount, Total		$ 578,000
Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total	14.50%
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Other	$ 1,525,594	$ 3,181,481
Domestic Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	38,399,914
Foreign Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	$ 21,785,348
Great Britain [Member]
Operating Loss Carryforwards [Line Items]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	20.00%	20.25%
UNITED KINGDOM | Domestic Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	$ 38,400,000

Segment Information (Details)

Segment Information (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Segment Reporting Information [Line Items]
Total	$ 58,364	$ 40,513
UNITED STATES
Segment Reporting Information [Line Items]
Total	28,849	32,373
UNITED KINGDOM
Segment Reporting Information [Line Items]
Total	$ 29,515	$ 8,140